Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Study of PRN1008 in Patients With Pemphigus

ClinicalTrials.gov ID: NCT03762265

Public ClinicalTrials.gov record NCT03762265. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor Rilzabrutinib (PRN1008) in Moderate to Severe Pemphigus

Study identification

NCT ID
NCT03762265
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Principia Biopharma, a Sanofi Company
Industry
Enrollment
131 participants

Conditions and interventions

Conditions

Interventions

  • Rilzabrutinib Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 7, 2019
Primary completion
Jul 29, 2021
Completion
Dec 16, 2021
Last update posted
Aug 1, 2023

2019 – 2021

United States locations

U.S. sites
14
U.S. states
10
U.S. cities
12
Facility City State ZIP Site status
Central Recruiting (Principia Biopharma) Boca Raton Florida 33433
Central Recruiting (Principia Biopharma) Coral Gables Florida 33134
Central Recruiting (Principia Biopharma) Atlanta Georgia 30322
Central Recruiting (Principia Biopharma) Ann Arbor Michigan 48103
Central Recruiting (Principia Biopharma) Ann Arbor Michigan 48109
Central Recruiting (Principia Biopharma) Rochester Minnesota 55905
Central Recruiting (Principia Biopharma) Albuquerque New Mexico 87131
Central Recruiting (Principia Biopharma) New York New York 10016
Central Recruiting (Principia Biopharma) New York New York 10028
Central Recruiting (Principia Biopharma) Chapel Hill North Carolina 27599
Central Recruiting (Principia Biopharma) Durham North Carolina 27710
Central Recruiting (Principia Biopharma) Cleveland Ohio 44106
Central Recruiting (Principia Biopharma) Austin Texas 78705
Central Recruiting (Principia Biopharma) Murray Utah 84107

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 74 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03762265, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 1, 2023 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03762265 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →